ALEXANDRA REZAZADEH
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology MINNEAPOLIS, MN NPI 1053843573
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology MN Kite Pharma, Inc. All categories
General Payments — all program years on this page
$2,790.56
- Category: General Payments
- Program years: PY2021–2023
- Record count: 25
- As of (CMS publication): 2026-01-23
Latest program year (PY2023): $912.20 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2023) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $912.20 | 8 |
By paying entity
Latest program year (PY2023) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Kite Pharma, Inc. | $241.61 | 2 |
| GENZYME CORPORATION | $125.00 | 1 |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 1 |
| Exelixis Inc. | $124.07 | 1 |
| Genmab U.S., Inc. | $110.99 | 1 |
| Acerta Pharma LLC | $95.36 | 1 |
| Karyopharm Therapeutics Inc. | $90.17 | 1 |
By program year
Records — PY2023 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1015450941 | E.R. Squibb & Sons, L.L.C. | $125.00 | 04/11/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1015777745 | AstraZeneca Pharmaceuticals LP | $95.36 | 05/16/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1025273031 | Kite Pharma, Inc. | $120.84 | 06/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1025273033 | Kite Pharma, Inc. | $120.77 | 06/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1044550501 | Exelixis Inc. | $124.07 | 05/03/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1049912803 | GENZYME CORPORATION | $125.00 | 03/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1051342073 | Genmab U.S., Inc. | $110.99 | 06/23/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1056896673 | Karyopharm Therapeutics Inc. | $90.17 | 02/15/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.